Protagonist Therapeutics (PTGX, Financial) has recently been the focus of analyst activity as HC Wainwright & Co. reiterated its rating and price target. According to the latest report dated June 3, 2025, analyst Douglas Tsao has reaffirmed a "Buy" rating for the biopharmaceutical company.
The price target remains unchanged at $80.00 USD, consistent with the previous target set by the analyst. This reiteration indicates confidence in Protagonist Therapeutics' (PTGX, Financial) current market position and potential future performance.
Investors and market watchers will likely keep a close eye on PTGX following this reaffirmation by HC Wainwright & Co. as the company continues to develop and progress within the healthcare sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Protagonist Therapeutics Inc (PTGX, Financial) is $69.00 with a high estimate of $82.00 and a low estimate of $41.00. The average target implies an upside of 37.59% from the current price of $50.15. More detailed estimate data can be found on the Protagonist Therapeutics Inc (PTGX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Protagonist Therapeutics Inc's (PTGX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
